Rockefeller Capital Management L.P. Purchases 20,000 Shares of Indivior PLC (NASDAQ:INDV)

Rockefeller Capital Management L.P. lifted its stake in Indivior PLC (NASDAQ:INDV) by 66.7% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 50,000 shares of the company’s stock after acquiring an additional 20,000 shares during the period. Rockefeller Capital Management L.P.’s holdings in Indivior were worth $488,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Indivior by 4.8% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 41,327 shares of the company’s stock valued at $408,000 after buying an additional 1,888 shares during the period. Cubist Systematic Strategies LLC raised its stake in Indivior by 32.0% during the second quarter. Cubist Systematic Strategies LLC now owns 25,236 shares of the company’s stock worth $407,000 after purchasing an additional 6,121 shares during the period. Bank of New York Mellon Corp purchased a new stake in Indivior in the second quarter valued at $188,000. VELA Investment Management LLC purchased a new position in Indivior during the second quarter worth about $235,000. Finally, XTX Topco Ltd purchased a new stake in Indivior in the second quarter valued at approximately $249,000. 60.33% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts recently weighed in on INDV shares. Piper Sandler restated an “overweight” rating and set a $16.00 target price (up previously from $15.00) on shares of Indivior in a research note on Friday, October 25th. Craig Hallum reduced their target price on shares of Indivior from $20.00 to $16.00 and set a “buy” rating for the company in a research note on Friday, October 11th.

Indivior Stock Up 2.3 %

INDV stock opened at $11.71 on Wednesday. The company’s 50 day simple moving average is $9.87 and its 200-day simple moving average is $12.00. Indivior PLC has a 12 month low of $7.33 and a 12 month high of $23.22. The firm has a market capitalization of $1.61 billion, a PE ratio of -292.75 and a beta of 0.75. The company has a debt-to-equity ratio of 23.50, a current ratio of 0.83 and a quick ratio of 0.65.

Indivior (NASDAQ:INDV) last posted its earnings results on Thursday, October 24th. The company reported $0.54 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.15. Indivior had a negative net margin of 0.17% and a negative return on equity of 351.08%. The business had revenue of $307.00 million for the quarter, compared to analysts’ expectations of $302.25 million. Equities analysts expect that Indivior PLC will post 1.66 earnings per share for the current fiscal year.

Indivior Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.